Xerostomia – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Xerostomia – Pipeline Review, H2 2019’, provides an overview of the Xerostomia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Xerostomia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Xerostomia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Xerostomia

– The report reviews pipeline therapeutics for Xerostomia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Xerostomia therapeutics and enlists all their major and minor projects

– The report assesses Xerostomia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Xerostomia”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Xerostomia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Xerostomia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“BioCurity Pharmaceuticals Inc

Capricor Therapeutics Inc

Humanetics Corp

Icure Pharmaceutical Inc

Lubris Biopharma

MeiraGTx Holdings Plc

MyX Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Xerostomia - Overview

Xerostomia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Xerostomia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Xerostomia - Companies Involved in Therapeutics Development

Capricor Therapeutics Inc

Cellix Bio Pvt Ltd

Humanetics Corp

Icure Pharmaceutical Inc

Lamellar Biomedical Ltd

MeiraGTx Holdings Plc

Xerostomia - Drug Profiles

A-00X - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAP-2003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerium oxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-1561 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Pulmonary Inflammation, Radiodermatitis and Xerostomia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ECF-843 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LMS-611 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pilocarpine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Xerostomia - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Xerostomia, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Xerostomia – Pipeline by BioCurity Pharmaceuticals Inc, H2 2019

Xerostomia – Pipeline by Capricor Therapeutics Inc, H2 2019

Xerostomia – Pipeline by Humanetics Corp, H2 2019

Xerostomia – Pipeline by Icure Pharmaceutical Inc, H2 2019

Xerostomia – Pipeline by Lubris Biopharma, H2 2019

Xerostomia – Pipeline by MeiraGTx Holdings Plc, H2 2019

Xerostomia – Pipeline by MyX Therapeutics Inc, H2 2019

Xerostomia – Dormant Projects, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Xerostomia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared